|Mauna Kea Technologies SA -- France Stock|| |
EUR 2.62 0.14 5.07%
Chief Devel. Officer and President of North America
Mr. Christopher E. Tihansky serves as resident, North America and Chief Development Officer at Mauna Kea Technologies SA. Previously, he served as President of its US subsidiary. He started his career as a Project Engineer then as a Sales Representative in orthopedics. In the mid1990s, he was Senior Healthcare Analyst at Genesis Merchant Group, an investment banking firm based in San Francisco. He then joined Telefex Medical where he was appointed Vice President and General Manager for the surgical instrument business. In 2003, Mr. Tihansky became President and Chief Executive Officer of Surgical Services, Inc
Age: 50 President Since 2015 MBA
33 1 48 24 03 45 http://www.maunakeatech.com
Tihansky holds an MBA from the University of San Diego, an M.S. in Biomedical Engineering from Drexel University and a B.S. in Mechanical Engineering from Lehigh University.
The company has return on total asset (ROA)
of (29.39) %
which means that it has lost $29.39 on every $100 spent on asset. This is way below average. Similarly, it shows return on equity (ROE)
of (77.19) %
meaning that it generated substantial loss on money invested by shareholders.
The company has accumulated 3.04 M in total debt with debt to equity ratio (D/E) of 27.2 indicating the company may have difficulties to generate enough cash to satisfy its financial obligations. Mauna Kea Technologies SA has Current Ratio of 2.7 suggesting that it is liquid and has the ability to pay its financial obligations in time and when they become due.
Mauna Kea Technologies S.A. develops, produces, and markets microendoscopes and probes, as well as related services. Mauna Kea Technologies SA (MKEA) is traded on Paris Stock Exchange in France. It is located in , rue d'EnghienParis, and employs 83 people.